Against the sky, the net profit increased nearly 60 times! Guangyuyuan's "report card" is bright and blind

Recently, guangyuyuan published its 2016 report card, realizing a revenue of 937 million yuan, a year-on-year increase of 118.70%, and a net profit of 123 million yuan attributable to shareholders of the listed company, a year-on-year increase of nearly 60 times, which can be said to be blinding How to achieve such a beautiful performance? None = "shifumousedownstyle ('shifu_bus_ ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; box sizing: border box! Im assistant; word wrap: break word! Im assistant; line height: 25.6px; border style: none solid; text align: Center; border bottom width: 1px; Border bottom color: rgb (0, 0, 0); "> in 2016, guangyuyuan's performance achieved explosive growth According to the annual report, guangyuyuan's operating revenue in 2016 was 937 million yuan, an increase of 118.70% year on year; the net profit attributable to shareholders of listed companies was 123 million yuan, an increase of 5948.84% compared with 2015 In addition, the company's net profit after deducting non recurring profit and loss attributable to shareholders of listed companies is 110 million yuan, the first profit after five consecutive years of losses, which is the most striking performance of Guangyu since the transformation of the pharmaceutical industry   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; box-sizing: border-box !im portant; word-wrap: break-word !im portant; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); "> the main reason for the surge in performance is that" traditional Chinese medicine + top-quality Chinese medicine + health wine "is the three driving force of guangyuyuan, which adheres to the industrial development strategy of" traditional Chinese medicine + top-quality Chinese medicine + health wine "and is based on the three business sectors It can be seen from Figure 1 that traditional Chinese medicine is still the main source of the company's sales and profits In 2016, the company achieved a new sales breakthrough of 580 million yuan, followed by high-quality Chinese medicine, with an operating revenue of 179 million yuan, both of which have a gross margin of more than 80% In 2016, in terms of traditional Chinese medicine, guangyuyuan achieved a total of 59336 drugstore terminals and 1834 hospitals above the second grade a through various channels such as business, OTC and hospital, which rapidly boosted the sales revenue of traditional Chinese medicine and achieved a new sales breakthrough In terms of high-quality traditional Chinese medicine, the company integrates internal resources and sharing advantages, gradually carries out the construction of national medical center, continuously explores the sales mode of high-quality traditional Chinese medicine, strengthens the promotion of self media, new media and other platforms, strengthens cooperation with traditional network media, improves brand image and strengthens market expansion and penetration in combination with online and offline sales channels In the aspect of health wine, the company continues to focus on the existing regional markets such as Shanxi and Jiangsu, focusing on the core terminals such as restaurant chains and famous tobacco hotels, increasing online promotion and marketing innovation of e-commerce platform, launching various forms of marketing and promotion activities around festivals and health solar terms offline, continuously improving product awareness, and ensuring steady growth of sales In 2016, guangyuyuan issued a total of 50.8061 million shares to Dongsheng Group, Dingsheng Jinhe and Panxin investment, with the issue price of 25.43 yuan / share, and purchased 40% of Shanxi guangyuyuan's total equity at the price of 1.292 billion yuan At the same time, 24.4967 million shares were issued in private and 862 million yuan of supporting funds were raised for the construction of guangyuyuan TCM industry and TCM technology research and development center Shanxi guangyuyuan is mainly engaged in the production and sales of traditional Chinese medicine, high-quality Chinese medicine and health wine It is a leading pharmaceutical enterprise in the production and sales of proprietary Chinese medicine and extended health wine Its main products are Guilingji, dingkundan, Angongniuhuang pill, niuhuangqingxin pill and other traditional classic Chinese medicine varieties Guilingji and dingkundanshui honeypill in guangyuyuan, Shanxi Province, are the main sales force of guangyuyuan In 2016, the production and sales volume of both of them increased significantly, and the sales revenue exceeded 100 million yuan, with 294 million yuan and 135 million yuan respectively Guilingji contributed the most gross profit, reaching 268 million yuan In 2016, Shanxi guangyuyuan launched two natural Angong Niuhuang pills and two natural Niuhuang Qingxin pills The gross profit margin of the two products is higher than that of the original boutique Angong Niuhuang pills and boutique Niuhuang Qingxin pills The sales proportion of the two products in the boutique traditional Chinese medicine reaches 38.75%, which may maintain a certain growth in the future As of December 31, 2016, guangyuyuan has five secondary subsidiaries, as shown in Table 3 It can be seen from table 3 that in 2016, Shanxi guangyuyuan achieved main business income of 937 million yuan and net profit of 154 million yuan In 2016, the main businesses of Beijing xinglinyuyuan, Ankang guangyuyuan and Shaanxi Dongsheng pharmaceutical had no income; the net profits of xinglinyuyuan and Beijing guangyuyuan lost 4.4834 million yuan and 7.3744 million yuan respectively; the net profits of Ankang guangyuyuan and Dongsheng pharmaceutical were only 151000 yuan and 2.3008 million yuan respectively, although they did not lose All of the above shows that guangyuyuan, Shanxi Province, has almost alone provoked the main beam of guangyuyuan's business revenue and plays an important role in the company After the fixed increase, guangyuyuan's shareholding ratio in Shanxi guangyuyuan increased from 55% to 95%, significantly increasing the company's net profit and net asset scale, laying a solid foundation for the company's future development After the completion of the fixed increase, Dongsheng Group's shareholding in guangyuyuan increased to 23.22%, increasing its control over the company, which is conducive to the stability of the company's organizational structure and the implementation of the long-term plan During the period, the cost control is good, and the three cost rates are all decreased It can be seen from Figure 2 that in 2016, guangyuyuan's sales expense rate, management expense rate and financial expense rate all showed a downward trend, in which the sales expense rate decreased by 5.74% and the management expense rate decreased by 6.64% As the subsidiary Shanxi guangyuyuan repaid 21.49 million bank borrowings with high interest rate, the financial expense rate decreased by 47.73% year on year, and the financial expense rate decreased by 0.9% year on year The company's revenue was fast Under the condition of rapid growth, the expense rate shows a downward trend, indicating that the company has achieved remarkable results in expense control, and the management and operation efficiency has been further improved   none="shifuMouseDownCard('shifu_c_026')" style="margin: 2em 0px 0px; padding: 0.5em 0px; max-width: 100%; font-family: inherit; font-size: 1em; font-weight: inherit; line-height: 25.6px; border-style: solid none; border-top-width: 1px; border-top-color: rgb(204, 204, 204); border-bottom-width: 1px; border-bottom-color: rgb(204, 204, 204); text-decoration: inherit; color: rgb(166, 166, 166); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> conclusion 2016 Guangyu has entered the first year of fast development The company keeps innovating marketing, strengthening market expansion and penetration, improving and deepening marketing channels, accelerating production capacity improvement and product structure optimization and upgrading, so that the company's operating revenue and net profit attributable to the shareholders of the parent company can grow rapidly Whether this proud achievement can be continued in 2017 remains to be seen!